UNASSIGNED: 88 Background: To assess and compare the biochemical failure free survival (BFFS), PSA kinetics and absolute PSA responses in @entity1 receiving radical radiotherapy for @entity263 ( @entity138 ) receiving either neoadjuvant @entity12195 or neoadjuvant LHRH agonist therapy. METHODS: A retrospective review of consecutive cases with @entity263 treated with BC monotherapy prior to radical radiotherapy was individually case matched to @entity1 treated with neoadjuvant @entity68825 monotherapy from April 2004 to December 2008. PSA kinetics and absolute pre- @entity138 , post neo-adjuvant hormone PSA ( @entity13261 -PSA) level and subsequent BFFS were analyzed. RESULTS: 65 @entity1 treated with BC monotherapy were individually matched with 65 @entity1 treated with LHRHa. The median follow-up was 44 months and 54 months respectively. There were no significant differences in pre-treatment @entity1 or @entity5 characteristics. Statistically significant differences were noted between groups in the @entity13261 -PSA with a geometric mean of 2.0ng/ml (range 0.1 - 11.2ng/ml) for BC @entity1 and 1.0ng/ml (range 0.1 - 11.1ng/ml) for LHRHa @entity1 (p<0.001). The geometric mean PSA halving time during the neo-adjuvant period of 14.6weeks (range 2 - 160weeks) in the BC treated group was statistically significantly different when compared to the mean of 16.1 weeks (range 2.1-96.8 weeks) for LHRHa @entity1 (p=0.056). There were however no differences in PSA velocity. A @entity13261 -PSA of <1.0ng/ml and <0.1ng/ml was seen in 16(24.6%) and 2 (3%) of the BC @entity1 and 34(52.3%) and 3(4.6%) of LHRHa @entity1 respectively. Phoenix biochemical failure was seen in 10(15.4%, 95%CI [8.6%, 26.1%]) and 8(12.3%, [6.4%, 22.5%) of BC and LHRHa @entity1 respectively. Neither @entity13261 -PSA level nor PSA kinetics during the neo-adjuvant period predict for subsequent BFFS at this duration of follow-up. CONCLUSIONS: In this case-matched study, we found that although neo-adjuvant BC therapy did not result in equivalent @entity13261 -PSA suppression when compared to neo-adjuvant LHRHa alone, there was no difference in biochemical failure rates between the cohorts at an overall median follow-up of 44 months. Longer follow-up is required.

Neoadjuvant hormone therapy for radical prostate radiotherapy: A case-matched study comparing XXXX to LHRH agonist therapy.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'men'] @entity12195 :: ('MESH:C053541', 'Chemical') :: ['bicalutamide'] @entity263 :: ('MESH:D011471', 'Disease') :: ['localized prostate cancer', 'prostate cancer'] @entity68825 :: ('D016729', 'Chemical') :: ['LHRHa'] @entity138 :: ('MESH:C563738', 'Disease') :: ['RT'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity13261 :: ('5630', 'Gene') :: ['PRPH']
@entity12195 :: (MESH:C053541,Chemical) :: ['bicalutamide']
